₩6,190.00 ($4.61)

+70.00 (+1.14%)

Weekly Expected Move ±3.9%

₩5709 ₩5949 ₩6190 ₩6431 ₩6671

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 40 · ₩71.4B mcap · 6M float · 0.406% daily turnover

Analysis Technicals Weather Peers

Revenue

$590.9B -10.1% ▼

5Y CAGR: -0.2%

Gross Profit

$215.1B -7.6% ▼

5Y CAGR: -2.7%

Operating Income

$12.1B +603.6% ▲

Net Income

$10.9B -82.7% ▼

EPS (Diluted)

$966.78 -80.9% ▼

EBITDA

$41.5B -66.7% ▼

5Y CAGR: +20.3%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$592.4B	$675.5B	$638.4B	$657.6B	$590.9B
YoY Growth	-0.7%	+14.0%	-5.5%	+3.0%	-10.1%
Cost of Revenue	$371.5B	$436.4B	$439.6B	$424.8B	$375.7B
Gross Profit	$220.8B	$239.1B	$198.9B	$232.8B	$215.1B
Gross Margin	37.3%	35.4%	31.2%	35.4%	36.4%
R&D Expenses	$109.8B	$119.4B	$108.0B	$55.9B	$0
SG&A Expenses	$85.3B	$106.0B	$65.2B	$71.3B	$0
Operating Expenses	$302.5B	$337.4B	$278.4B	$235.2B	$203.0B
Operating Income	-$81.7B	-$98.3B	-$79.6B	-$2.4B	$12.1B
Operating Margin	-13.8%	-14.5%	-12.5%	-0.4%	2.1%
Interest Expense	$15.1B	$17.2B	$30.1B	$34.1B	$23.2B
Income Before Tax	-$176.5B	-$173.0B	-$132.1B	$53.5B	$30.3B
Tax Expense	-$41.8B	$21.6B	-$13.3B	-$2.1B	$11.1B
Net Income	-$134.7B	-$194.5B	-$59.6B	$63.0B	$10.9B
Net Margin	-22.7%	-28.8%	-9.3%	9.6%	1.8%
EPS (Diluted)	$-11928.34	$-17224.76	$-5276.86	$5063.47	$966.78
EBITDA	-$121.3B	-$116.3B	-$64.0B	$124.4B	$41.5B
Shares Outstanding	11M	11M	11M	13M	12M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$166.6B	$166.3B	$149.8B	$148.8B	$150.5B	$153.8B	$148.9B	$154.0B
Cost of Revenue	$109.4B	$105.5B	$95.2B	$93.6B	$90.3B	$97.1B	$92.2B	$98.0B
Gross Profit	$57.1B	$60.9B	$54.6B	$55.2B	$60.2B	$56.7B	$56.6B	$56.0B
Gross Margin	34.3%	36.6%	36.4%	37.1%	40.0%	36.9%	38.0%	36.4%
R&D Expenses	$0	$11.2B	$8.0B	$9.1B	$9.3B	$9.1B	$8.6B	$0
SG&A Expenses	$57.0B	$16.6B	$50.5B	$21.2B	$17.4B	-$8.4B	$16.5B	$41.1B
Operating Expenses	$57.0B	$56.2B	$50.5B	$57.2B	$51.4B	$51.6B	$47.5B	$52.4B
Operating Income	$105M	$4.6B	$4.1B	-$2.0B	$6.3B	$7.3B	$9.1B	$3.6B
Operating Margin	0.1%	2.8%	2.7%	-1.3%	4.2%	4.7%	6.1%	2.3%
Interest Expense	$7.7B	$8.2B	$7.2B	$6.7B	$5.7B	$3.6B	$2.3B	$2.2B
Income Before Tax	-$14.7B	$73.0B	-$4.6B	-$10.3B	$24.6B	$21.1B	$6.5B	$1.1B
Tax Expense	$1.3B	-$10.1B	$644M	-$821M	$10.0B	$1.4B	$698M	-$1.7B
Net Income	-$16.0B	$75.9B	-$4.8B	-$5.2B	$993M	$19.3B	$1.4B	-$16M
Net Margin	-9.6%	45.6%	-3.2%	-3.5%	0.7%	12.5%	1.0%	-0.0%
EPS (Diluted)	$-662.04	$4385.76	$-421.33	$-460.00	$87.00	$2443.89	$123.31	$-1.00
EBITDA	$105M	$90.8B	$54.6B	$3.9B	$39.1B	-$12.6B	$16.1B	$10.6B
Shares Outstanding	11M	12M	11M	11M	11M	8M	47M	85M

000230.KS KSC